188 related articles for article (PubMed ID: 23836412)
1. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Gulley JL; Heery CR; Madan RA; Walter BA; Merino MJ; Dahut WL; Tsang KY; Schlom J; Pinto PA
Cancer Immunol Immunother; 2013 Sep; 62(9):1521-31. PubMed ID: 23836412
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
3. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Farsaci B; Jochems C; Grenga I; Donahue RN; Tucker JA; Pinto PA; Merino MJ; Heery CR; Madan RA; Gulley JL; Schlom J
Int J Cancer; 2014 Aug; 135(4):862-70. PubMed ID: 24474335
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
McNeel DG; Chen YH; Gulley JL; Dwyer AJ; Madan RA; Carducci MA; DiPaola RS
Hum Vaccin Immunother; 2015; 11(10):2469-74. PubMed ID: 26111351
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
7. Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).
Merino MJ; Pinto PA; Moreno V; Gil S; Schlom J; Gulley JL
Hum Pathol; 2018 Aug; 78():72-78. PubMed ID: 29709495
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Lechleider RJ; Arlen PM; Tsang KY; Steinberg SM; Yokokawa J; Cereda V; Camphausen K; Schlom J; Dahut WL; Gulley JL
Clin Cancer Res; 2008 Aug; 14(16):5284-91. PubMed ID: 18698048
[TBL] [Abstract][Full Text] [Related]
9. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
[TBL] [Abstract][Full Text] [Related]
10. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
DiPaola RS; Chen YH; Bubley GJ; Stein MN; Hahn NM; Carducci MA; Lattime EC; Gulley JL; Arlen PM; Butterfield LH; Wilding G
Eur Urol; 2015 Sep; 68(3):365-71. PubMed ID: 25533418
[TBL] [Abstract][Full Text] [Related]
11. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
[TBL] [Abstract][Full Text] [Related]
14. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Gulley JL; Madan RA; Tsang KY; Jochems C; Marté JL; Farsaci B; Tucker JA; Hodge JW; Liewehr DJ; Steinberg SM; Heery CR; Schlom J
Cancer Immunol Res; 2014 Feb; 2(2):133-41. PubMed ID: 24778277
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Eder JP; Kantoff PW; Roper K; Xu GX; Bubley GJ; Boyden J; Gritz L; Mazzara G; Oh WK; Arlen P; Tsang KY; Panicali D; Schlom J; Kufe DW
Clin Cancer Res; 2000 May; 6(5):1632-8. PubMed ID: 10815880
[TBL] [Abstract][Full Text] [Related]
16. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Gulley JL; Arlen PM; Madan RA; Tsang KY; Pazdur MP; Skarupa L; Jones JL; Poole DJ; Higgins JP; Hodge JW; Cereda V; Vergati M; Steinberg SM; Halabi S; Jones E; Chen C; Parnes H; Wright JJ; Dahut WL; Schlom J
Cancer Immunol Immunother; 2010 May; 59(5):663-74. PubMed ID: 19890632
[TBL] [Abstract][Full Text] [Related]
17. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
18. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
19. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
Madan RA; Arlen PM; Mohebtash M; Hodge JW; Gulley JL
Expert Opin Investig Drugs; 2009 Jul; 18(7):1001-11. PubMed ID: 19548854
[TBL] [Abstract][Full Text] [Related]
20. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
